PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arsMary Ann Liebert, Inc.Mary Ann Liebert, Inc.JournalsSearchAlerts
Antioxidants & Redox Signaling
 
Antioxid Redox Signal. 2012 December 1; 17(11): 1580–1589.
PMCID: PMC3448939

The Electrophile Responsive Proteome: Integrating Proteomics and Lipidomics with Cellular Function

Abstract

Significance: The process of lipid peroxidation is emerging as an important mechanism that mediates the post-translational modification of proteins. Through advanced analytical techniques, lipidomics is now emerging as a critical factor in our understanding of the pathology of a broad range of diseases. Recent Advances: During enzymatic or nonenzymatic lipid peroxidation, the simple structure of an unsaturated fatty acid is converted to an oxylipidome, many members of which are electrophilic and form the reactive lipid species (RLS). This aspect of lipid biology is particularly important, as it directly connects lipidomics with proteomics through the post-translational modification of a sub-proteome in the cell. This arises, because the electrophilic members of the oxylipidome react with proteins at nucleophilic amino-acid residues and so change their structure and function to form electrophile-responsive proteomes (ERP). Critical Issues: Biological systems have relatively few but well-defined and mechanistically distinct pro-oxidant pathways generating RLS. Defining the ERPs and the mechanisms underlying their formation and action has been a major focus for the field of lipidomics and redox signaling. Future Directions: We propose that a unique oxylipidome can be defined for specific oxidants and will predict the biological responses through the reaction with proteins to form a specific ERP. In this review, we will describe the ERPs that modulate antioxidant and anti-inflammatory protective pathways, including the activation of Keap1/Nrf2 and the promotion of cell death through interactions with mitochondria. Antioxid. Redox Signal. 17, 1580–1589.

Introduction

The oxidation of polyunsaturated fatty acids (PUFAs), such as arachidonic acid, generates a broad range of oxidation products that have been used over several decades as markers of oxidative stress (15, 62). Oxidized lipids are readily generated in biological systems because of the availability of PUFAs that are easily oxidized and the proximity to the sites of formation of pro-oxidants by both controlled and uncontrolled mechanisms in cells. Many of the oxidized lipids are electrophilic and are, therefore, capable of modifying nucleophilic centers in the cell. We, therefore, call these oxidized lipids the reactive lipid species (RLS). The reactions of RLS include those with amino groups on lipids and DNA and a broad range of amino-acid residues, most notably cysteine, histidine, lysine, and arginine. RLS are biologically important, because they modify proteins associated with signal transduction (18, 51, 90), energy production (21), mitochondrial respiration (33, 46), and cell death pathways (36, 42, 45, 89). At low levels, many RLS play a role in cell signaling events (16, 25, 91, 96) and in this case, control the formation of reactive oxygen species (ROS)/reactive nitrogen species (RNS) and have a protective role (5, 28, 37, 101). However, in pathology, the role of RLS changes dramatically. For example, oxidized lipids such as 4-hydroxy-trans-2-nonenal (HNE) and isoprostanes are produced in the diseased heart and modify proteins, thus inhibiting their normal function (54, 62, 79).

Indeed, the widespread detection of the products of lipid peroxidation, from both enzymatic and nonenzymatic sources, in a broad range of pathological conditions has led to the concept that RLS may also contribute to disease progression (3, 14, 39, 55, 67). For example, in cardiovascular disease, the underlying inflammatory process, which through regulation of gene expression by nuclear factor kappa B (NFκB) can increase cyclo-oxygenase (COX)-2 as well as PLA2, leads to enhanced oxidation of fatty acids (88, 100). In ischemia-reperfusion injury, hemolysis occurs, leading to an increase in free-radical catalyzed lipid peroxidation due to the release of hemoglobin and free heme (44, 47). In hemolytic anemias, increased levels of RLS have been reported, and lower concentrations of the lipid radical scavenger Vitamin E are also consistent with increased lipid peroxidation (1, 28, 44, 65, 69, 86). Several factors in heart failure, including increases in ROS from xanthine oxidase and the mitochondria, enhance the oxidation of phospholipids (4, 61, 84, 92).

While it is then established that these pathological processes are associated with lipid peroxidation, the mechanisms through which they mediate biological effects are less clear. More recently, these concepts have been further developed to encompass the finding that low levels of RLS activate the signal transduction pathways which control the levels of intracellular antioxidants such as glutathione (GSH) and heme oxygenase-1 (17, 28, 56, 71, 101). A contemporary view of lipid peroxidation is that oxidized lipids can elicit different cellular effects depending on the RLS present (the oxylipidome), their concentrations, and, importantly, their reactivity with biomolecules, including lipids, DNA, and proteins (6, 38, 51, 63). The focus of this review will be to discuss new concepts through which the oxylipidome modulates biological functions through the formation of electrophile-responsive proteomes (ERP) in cells.

Generation of Oxylipidomes in Biological Systems

Lipid peroxidation in cells can occur through controlled enzymatic pathways, including the lipoxygenase (LOX), COX or cytochrome p450 enzymes (43, 57, 74, 83, 94). Some of these enzymes are constitutive and contribute a low level of oxidized lipids with a predominantly autocrine function, and some are inducible and generate high levels of oxidized lipids that exhibit both autocrine and paracrine functions. Nonspecific lipid peroxidation describes any oxidation process that is not mediated by a controlled enzymatic mechanism. Recent advances in mass spectrometry are overcoming difficulties in defining the complete oxylipidome produced by different mechanisms of lipid peroxidation, allowing for the characterization of the regulatory oxylipidomes for COXs and LOXs (27, 97). It has been established that the oxylipidome generated by controlled enzymatic pathways (e.g., LOX and COX) and nonspecific lipid peroxidation are distinct in two important areas: (i) The isomers, for example, F2-isoprostanes, generated from nonspecific lipid peroxidation, show little stereospecificity. In contrast, the enzymatic mechanism of lipid peroxidation generates specific and limited numbers of stereoisomers, for example, PGF and, hence, different oxylipidomes (26, 32, 98). (ii) The nonspecific oxylipidome is populated by RLS not formed by enzymatic mechanisms. These include many aldehydes, as well as nitrated or chlorinated lipids formed by RNS or chlorine species, respectively (2, 24, 93, 99). Selected examples of the members of the oxylipidomes produced by nonspecific and specific lipid peroxidation are shown in Figure 1. From the Venn diagram, it is obvious that biological oxylipidomes are composed of varying proportions of different RLS with distinct properties and reactivities as shown in Figure 2. From this, it is then a logical step to propose that the biological effects arising from an oxylipidome will be related to how the members are distributed among these functionally distinct classes of lipid electrophiles.

FIG. 1.
Oxylipidomics: the formation of structurally diverse reactive lipid species (RLS). (A) As can be seen in this Venn diagram, the lipid peroxidation products formed depend on the method of initiation. The black and white circles represent the oxylipidomes ...
FIG. 2.
Products of enzymatic and nonenzymatic lipid peroxidation. Products of enzymatic and nonenzymatic lipid peroxidation are different. While enzymatic lipid peroxidation forms electrophilic species (*denotes reactive carbon) such as the cyclopentenone prostaglandins ...

The biological effects of RLS build on a considerable amount of research that has defined the biological effects of a candidate member of an oxylipidome in cells or more complex animal models of a disease. Two typical, but structurally distinct examples (Fig. 2) are the electrophilic lipid aldehydes HNE, a nonspecific lipid peroxidation product and the cyclopentenone prostaglandin, 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) (12, 72, 80). From such studies, some generalized conclusions of the biological outcomes associated with specific and nonspecific lipid peroxidation have been achieved, and these are outlined in Figure 3. The enzymatic lipid peroxidation products can increase cytoprotective pathways in the cell through modification of cysteine residues in cell signaling proteins, such as the Keap1/nuclear factor-erythroid 2 related factor (Nrf2) system (Fig. 4B) (40, 49, 51, 68, 85). In contrast, the nonenzymatic lipid peroxidation products while also showing some cross-over activation of the same cytoprotective pathways damage proteins, cause bioenergetic dysfunction and depletion of cellular antioxidants, such as GSH (52). This is partly due to the differential reactivity of oxidized lipids that are nonenzymatically produced. Highly RLS such as isoketals, isofurans, and aldehydes (such as 4-oxo-2-nonenal) are formed by free-radical catalyzed lipid peroxidation and unlike softer electrophiles, these react with amino acids other than cysteine and are, therefore, less specific. It is important to note that if the concentrations of the enzymatic lipid peroxidation products are increased beyond the physiological levels, then they induce the same pathological responses as the nonspecific lipid peroxidation products (49).

FIG. 3.
The effects of lipid peroxidation on cell function. Both positive and negative effects of lipid peroxidation products have been reported in the literature. During pathology, nonenzymatic sources of lipid peroxidation, including various oxidants and heme ...
FIG. 4.
Modification of protein targets determines whether cellular response leads to physiological changes or pathology. The proteomes modified by RLS determines cellular fate. Two examples are the modification of Keap1, which leads to increased antioxidant ...

The Relationship Between the Oxylipidome and ERPs

An important and technically challenging problem has been the identification of the relationship between the oxylipidome and the protein targets (the ERP) through which a biological response can be initiated. As noted earlier, the structurally different RLS result in a range of electrophilicities that changes their reactivity with the nucleophilic amino-acid residues in proteins. For example, the aldehyde HNE is a reactive electrophile forming adducts with histidine, cysteine, and lysine residues (34), whereas a cyclopentenone 15d-PGJ2 is more selective for protein cysteine residues (51, 78, 81). From this, we hypothesize that the proteins modified by any complex oxylipidome will be both a property of the mechanism of lipid peroxidation and the nucleophilic proteome to which they are exposed. The implication of this hypothesis is that the Venn diagram in Figure 1 should map onto a corresponding ERP, as shown in Figure 5. In this scheme, we show several enzymatic and nonenzymatic pathways that can lead to lipid peroxidation in biological membranes, in this case, the mitochondrion (Fig. 5A). The oxidation reaction leads to distinct oxylipidomes (a–e) which will be composed of different RLS that are then exposed to a proteome containing reactive nucleophilic amino-acid residues. This results in different ERPs that we have represented as 3 hypothetical different protein spot patterns for RLS-protein adducts a, b, and c. In Figure 5B, the putative relationship between ERP-a, b, and c with regard to biological responses is illustrated. The physiological/cytoprotective ERP-a can be ascribed to cysteine modification, whereas ERP-c is dominated by protein damage and bioenergetic dysfunction. ERP-b is an intermediate state in which the cytoprotective and cytotoxic pathways are in tension and is the arena in which therapeutic intervention could result in maximum benefit.

FIG. 5.
The proteomes modified by oxylipidome. (A) Lipid peroxidation can be initiated by a number of diverse mechanisms such as Mb, inducible nitric oxide synthase (iNOS), and COX, as shown here. Since each initiating mechanism has distinct attributes, this ...

Due to the importance of thiol modification in redox signaling, many studies have focused on the role of cysteine modification in eliciting the effects of various electrophiles. While the modification of a cysteine can lead to pathological effects if, for example, this amino acid is a part of the active site of an enzyme, then it is becoming increasingly appreciated that the modification of thiol residues can lead to physiological cell signaling (Fig. 5B). Interestingly, recent studies have demonstrated that the complete thiol-reactive ERP in a cell can be defined using two different, biotin-tagged electrophiles, PEO-IAB (biotinyl-iodoacetamidyl-3, 6-dioxaoctanediamine) and BMCC (1-biotinamido-4-(4′[maleimidoethylcyclohexane]-carboxamido) butane) with a specificity for reactions with cysteine residues (16). Approximately 500 cytosolic and nuclear proteins were modified, and of these, only 14% were modified by both electrophiles. This suggests that even within the population of electrophiles that react with cysteine residues there are subpopulations of differing selectivity. In a separate experiment, a distinct mitochondrial ERP was also identified. These data support the concept that the modification of proteomes by electrophiles is selective depending on both the electrophile and the local environment in which the reactive protein nucleophiles are located (16). It is important to note that these studies using thiol-specific reagents at high concentrations identify the thiol ERP which will be distinct from the ERP generated by more reactive electrophilic lipids.

The Cytoprotective ERP

A low-abundance thiol proteome, which controls redox signaling pathways and leads to cytoprotection in the cell, is activated by electrophiles (11, 13, 41, 77). The pathways have a common target in a low pKa reactive cysteine residue controlling the activity of a regulatory cell signaling molecule (13, 37). Members of this ERP include Keap1, which regulates the transcription of antioxidant enzymes, the heat shock family, which control protein folding, and the NFκB system, which regulates the transcription of pro-inflammatory proteins (37, 77). Interestingly, recent studies also suggest that the Nrf2 transcription factor coregulates the autophagy pathway, and electrophilic signaling may also be important in handling oxidatively damaged or aggregated proteins or organelles (75, 76).

Perhaps the best understood electrophile sensor in the cell is Keap1 (29, 59). This protein expresses an array of thiol sensors that detect electrophiles and other thiol reactive molecules differentially (59). The Keap1/Nrf2 pathway is activated by electrophilic lipid oxidation products, and complex oxylipidomes such as oxidized low-density lipoprotein (19, 50, 51, 56). The molecular mechanism for the transcriptional regulation of antioxidant enzymes is mediated, in part, through the dissociation of the transcription factor Nrf2 from its cytoplasmic binding protein Keap1 and binding to the electrophile response element or antioxidant response element (51, 66) as shown in Figure 4B. The control of cell signaling requires a reversal mechanism that prevents permanent activation. In the case of electrophilic signaling, the covalent modification of protein thiols by electrophiles is reversed by the proteasomal degradation of the modified protein (35, 58). Another interesting feature of electrophile signaling is that the formation of a covalent bond between the RLS and a signaling protein allows the accumulation of a signal over time (68). This finding reconciles the long-standing problem in the electrophile signaling field that the free forms of RLS are invariably found at low concentrations in biological systems and below that required to initiate the same signaling pathways with a pure electrophile in cell cultures. Thus, in the case of the ERP, there is a “covalent advantage” to signaling through the covalent modification of the nucleophilic protein target (17, 68). Since, in the model we propose (Fig. 5) the cell responds to an ERP, the accumulation of a covalent adduct offers an additional level of regulation. This could occur through modulating the composition of the ERP through differential proteasomal-dependent degradation of members of the proteome.

An interesting possibility which is now emerging is that the mitochondrion serves as a generator of low levels of endogenous RLS that contributes to the phenomenon of retrograde signaling in which the mitochondrion communicates with the nucleus. In support of this concept, cell signaling mediated by the promotion of mitochondrial ROS is inhibited by mitochondrially targeted, lipid radical scavengers, suggesting that mitochondrial hydrogen peroxide can be transduced to a lipid-derived electrophilic signal (9, 95). In endothelial cells, it has recently been shown that the Keap1/Nrf2 induction by 15d-PGJ2 of the antioxidant enzyme heme oxygenase-1 requires the participation of the mitochondria and that Keap1 can be tethered to the mitochondrion (53, 73). A critical cell signaling pathway involved in cardioprotection is known as ischemic preconditioning. The finding is that brief periods of mild ischemia result in protection of the heart from a more severe ischemic episode. A recent study has shown that electrophilic nitroalkenes are formed in the mitochondria and are cardioprotective (64). The molecular targets are still unclear but appear to involve mild uncoupling.

The Cytotoxic ERP

Defining the targets of electrophiles in cells that promote cell death has been more challenging, as this typically requires much more reactive electrophiles at high concentrations. Interestingly, more reactive electrophiles, such as HNE, have been shown to modify and inhibit the function of the proteasome, removing one key mechanism of degrading proteins modified by these electrophiles (22, 23). This modification is one key example of a detrimental modification by RLS (Fig. 4B) and demonstrates a means whereby low concentrations of an electrophile could result in prolonged dysfunction due to the inability to remove modified proteins.

The activation of key signaling pathways involving cell death has been reported for electrophilic lipids, including p53 (42). Not surprisingly, the mitochondria have emerged as a potential mediator of these effects. The release of cytochrome c from the organelle is one of the key steps in apoptosis and is regulated by the interaction of cytochrome c with cardiolipin. Oxidation and the formation of RLS have been shown to be a key step in the apoptotic cascade (39). Experiments with candidate lipid electrophiles have identified some of the key steps in the cytotoxic responses to electrophiles. Not surprisingly, HNE has featured prominently in these studies and has been shown to induce bioenergetic dysfunction, mitochondrial ROS in both isolated mitochondrial and cells (10, 31). There are multiple targets in the mitochondrion that could be contributing to bioenergetic function, and we would propose that it is the composite ERP which determines the overall bioenergetic dysfunction. For example, in a cellular setting, we have observed an increased proton leak that indicates damage to the ion transport or integrity of the inner mitochondrial membrane and decreased maximal respiration which is consistent with modification of the respiratory chain (31, 82). An interesting example of RLS-induced mitochondrial dysfunction occurs on exposure of cells to free heme. We have recently shown that the oxidant hemin increases lipid peroxidation and inhibits mitochondrial function in endothelial cells (30). The modification of proteins by RLS and alterations of mitochondrial function are attenuated by α-tocopherol, suggesting an important contribution by lipid peroxidation and inducing mitophagy (30). Indeed, the lipid peroxidation product HNE has been shown as modifying both complexes III and IV, and promoting uncoupling in isolated mitochondria (7, 8).

The permeability transition pore in the mitochondria is a complex multi-component channel intimately involved in both necrotic and apoptotic cell death (48). The regulation of the pore is highly dependent on thiol modification and can be modulated by RLS (60). For example, the exposure of mitochondria to cyclopentenone, 15d-PGJ2, results in a complex ERP associated with increased sensitivity to the mitochondrially induced permeability transition.

The mitochondrion may be a key integrating center for electrophile-dependent redox cell signaling because of the high pH in the mitochondrial matrix. This results in mitochondrial protein thiols being present in the thiolate form, which is more reactive with electrophiles. As discussed in the previous section, the localized production of mitochondrial ROS could control the production of endogenous electrophiles for cell signaling. Exogenous electrophilic lipids have also been shown to localize with the mitochondrion and modify proteins in this subcellular compartment.

Taken together, these data strongly support the concept that the mitochondrial ERP may predominantly promote pro-death signaling, whereas the cytosolic signaling pathways are cytoprotective, albeit with some cross-talk with the mitochondrion. To test this, we have taken the electrophile 15d-PGJ2 and synthesized a mitochondrial derivative (mito-15d-PGJ2). When compared with the native 15d-PGJ2, we found mito-15d-PGJ2 that was essentially incapable of inducing the Keap1/Nrf2 pathway and promoted bioenergetic dysfunction and apoptotic cell death (20). These data suggest that the ERPs are susceptible to pharmacological manipulation, and this will allow the differential control of cell signaling.

Summary

An important concept that has emerged in our understanding of oxidative stress in disease is that RLS modify the function of proteomes, not just single targets (70, 87, 93) (Fig. 5). Despite the success generated by the newer technologies capable of defining the oxylipidome, the resulting rich datasets are overwhelming the capacity of investigators to interpret this information. Further understanding of how oxylipidomics can explain biological effects will require the development of new bioinformatics platforms that integrate the data from lipidomics, protein modification, cell signaling, and cellular responses. This will be essential to address a key basic mechanistic question in redox biology: How does lipid peroxidation contribute to the pathophysiology of disease? In this review, we proposed a new paradigm which encompasses the fact that while lipid peroxidation is a consistent feature of multiple disease processes, the abundant literature in this area of redox biology reveals multiple protein targets (ERPs) that could elicit the biological response in question. The new concept is that it is the integrated behavior of the whole proteome which is responsible, not any given protein target in isolation, and this can be revealed through emerging technologies capable of integrating the bioinformatics datasets that relate oxylipidome with the ERPs and biological effects.

Abbreviations Used

15d-PGJ2
15-deoxy-Δ12,14-prostaglandin J2
COX
cyclo-oxygenase
EpRE
electrophile response element
ERP
electrophile-responsive proteome
GSH
glutathione
Hb
hemoglobin
HNE
4-hydroxy-trans-2-nonenal
iNOS
inducible nitric oxide synthase
Keap-1
kelch-like erythroid cell derived protein with CNC homology (ECH)–associated protein–1
LOX
lipoxygenase
Mb
myoglobin
NFκB
nuclear factor kappa b
NO
nitric oxide
Nrf2
nuclear factor-erythroid 2 related factor
ONOO
peroxynitrite
PUFA
polyunsaturated fatty acid
RLS
reactive lipid species
RNS
reactive nitrogen species
ROS
reactive oxygen species

Acknowledgments

This work was supported by NIH R01 Grants ES10167, AA13395, DK075867 (to V.D.U.), P50 AT00477, R21 AT004661, U54 CA100949 (to S.B.), and HL096638 (to A.L.). The authors have no financial conflicts of interest related to this work.

References

1. Amer J. Ghoti H. Rachmilewitz E. Koren A. Levin C. Fibach E. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol. 2006;132:108–113. [PubMed]
2. Baker PR. Schopfer FJ. O'Donnell VB. Freeman BA. Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids. Free Radic Biol Med. 2009;46:989–1003. [PMC free article] [PubMed]
3. Basu S. Helmersson J. Factors regulating isoprostane formation in vivo. Antioxid Redox Signal. 2005;7:221–235. [PubMed]
4. Berry CE. Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555:589–606. [PubMed]
5. Cadenas E. Mitochondrial free radical production and cell signaling. Mol Aspects Med. 2004;25:17–26. [PubMed]
6. Ceaser EK. Moellering DR. Shiva S. Ramachandran A. Landar A. Venkartraman A. Crawford J. Patel R. Dickinson DA. Ulasova E. Ji S. Darley-Usmar VM. Mechanisms of signal transduction mediated by oxidized lipids: the role of the electrophile-responsive proteome. Biochem Soc Trans. 2004;32:151–155. [PubMed]
7. Chen J. Henderson GI. Freeman GL. Role of 4-hydroxynonenal in modification of cytochrome c oxidase in ischemia/reperfused rat heart. J Mol Cell Cardiol. 2001;33:1919–1927. [PubMed]
8. Chen J. Robinson NC. Schenker S. Frosto TA. Henderson GI. Formation of 4-hydroxynonenal adducts with cytochrome c oxidase in rats following short-term ethanol intake. Hepatology. 1999;29:1792–1798. [PubMed]
9. Chen K. Thomas SR. Albano A. Murphy MP. Keaney JF., Jr. Mitochondrial function is required for hydrogen peroxide-induced growth factor receptor transactivation and downstream signaling. J Biol Chem. 2004;279:35079–35086. [PubMed]
10. Choksi KB. Boylston WH. Rabek JP. Widger WR. Papaconstantinou J. Oxidatively damaged proteins of heart mitochondrial electron transport complexes. Biochim Biophys Acta. 2004;1688:95–101. [PubMed]
11. Chouchani ET. James AM. Fearnley IM. Lilley KS. Murphy MP. Proteomic approaches to the characterization of protein thiol modification. Curr Opin Chem Biol. 2011;15:120–128. [PMC free article] [PubMed]
12. Codreanu SG. Zhang B. Sobecki SM. Billheimer DD. Liebler DC. Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal. Mol Cell Proteomics. 2009;8:670–680. [PMC free article] [PubMed]
13. Cooper CE. Patel RP. Brookes PS. Darley-Usmar VM. Nanotransducers in cellular redox signaling: modification of thiols by reactive oxygen and nitrogen species. Trends Biochem Sci. 2002;27:489–492. [PubMed]
14. Davi G. Falco A. Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal. 2005;7:256–268. [PubMed]
15. Davies SS. Roberts LJ., 2nd F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med. 2011;50:559–566. [PMC free article] [PubMed]
16. Dennehy MK. Richards KA. Wernke GR. Shyr Y. Liebler DC. Cytosolic and nuclear protein targets of thiol-reactive electrophiles. Chem Res Toxicol. 2006;19:20–29. [PubMed]
17. Dickinson DA. Darley-Usmar VM. Landar A. Dalle-Donne I. Scaloni A. Butterfield DA. The covalent advantage: a new paradigm for cell signaling mediated by thiol reactive lipid oxidation products. In: Dalle-Donne I, editor; Scaloni A, editor; Butterfield DA, editor. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases. Hoboken, NJ: John Wiley & Sons, Inc.; 2006. pp. 345–367.
18. Dickinson DA. Levonen AL. Moellering DR. Arnold EK. Zhang H. Darley-Usmar VM. Forman HJ. Human glutamate cysteine ligase gene regulation through the electrophile response element. Free Radic Biol Med. 2004;37:1152–1159. [PubMed]
19. Dickinson DA. Moellering DR. Iles KE. Patel RP. Levonen AL. Wigley A. Darley-Usmar VM. Forman HJ. Cytoprotection against oxidative stress and the regulation of glutathione synthesis. Biol Chem. 2003;384:527–537. [PubMed]
20. Diers AR. Higdon AN. Ricart KC. Johnson MS. Agarwal A. Kalyanaraman B. Landar A. Darley-Usmar VM. Mitochondrial targeting of the electrophilic lipid 15-deoxy-Delta12,14-prostaglandin J2 increases apoptotic efficacy via redox cell signalling mechanisms. Biochem J. 2010;426:31–41. [PMC free article] [PubMed]
21. Echtay KS. Esteves TC. Pakay JL. Jekabsons MB. Lambert AJ. Portero-Otin M. Pamplona R. Vidal-Puig AJ. Wang S. Roebuck SJ. Brand MD. A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling. EMBO J. 2003;22:4103–4110. [PubMed]
22. Farout L. Mary J. Vinh J. Szweda LI. Friguet B. Inactivation of the proteasome by 4-hydroxy-2-nonenal is site specific and dependant on 20S proteasome subtypes. Arch Biochem Biophys. 2006;453:135–142. [PubMed]
23. Ferrington DA. Kapphahn RJ. Catalytic site-specific inhibition of the 20S proteasome by 4-hydroxynonenal. FEBS Lett. 2004;578:217–223. [PubMed]
24. Ford DA. Lipid oxidation by hypochlorous acid: chlorinated lipids in atherosclerosis and myocardial ischemia. Clin Lipidol. 2010;5:835–852. [PMC free article] [PubMed]
25. Galvani S. Coatrieux C. Elbaz M. Grazide MH. Thiers JC. Parini A. Uchida K. Kamar N. Rostaing L. Baltas M. Salvayre R. Negre-Salvayre A. Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med. 2008;45:1457–1467. [PubMed]
26. Gross RW. Han X. Lipidomics at the interface of structure and function in systems biology. Chem Biol. 2011;18:284–291. [PMC free article] [PubMed]
27. Gross RW. Han X. Shotgun lipidomics of neutral lipids as an enabling technology for elucidation of lipid-related diseases. Am J Physiol Endocrinol Metab. 2009;297:E297–E303. [PubMed]
28. Gutierrez J. Ballinger SW. Darley-Usmar VM. Landar A. Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ Res. 2006;99:924–932. [PubMed]
29. Hayes JD. McMahon M. Chowdhry S. Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 2010;13:1713–1748. [PubMed]
30. Higdon AN. Benavides GA. Chacko B. Ouyang X. Johnson MS. Landar A. Zhang J. Darley-Usmar V. Hemin causes mitochondrial dysfunction in endothelial cells through promoting lipid peroxidation: the protective role of autophagy. Am J Physiol. 2012 doi: 10.1152/ajpheart.00584.2011. [Epub ahead of print] [PubMed] [Cross Ref]
31. Hill BG. Dranka BP. Zou L. Chatham JC. Darley-Usmar VM. Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenal. Biochem J. 2009;424:99–107. [PMC free article] [PubMed]
32. Hu C. Hoene M. Zhao X. Haring HU. Schleicher E. Lehmann R. Han X. Xu G. Weigert C. Lipidomics analysis reveals efficient storage of hepatic triacylglycerides enriched in unsaturated fatty acids after one bout of exercise in mice. PLoS One. 2010;5:e13318. [PMC free article] [PubMed]
33. Humphries KM. Yoo Y. Szweda LI. Inhibition of NADH-linked mitochondrial respiration by 4-hydroxy-2-nonenal. Biochemistry. 1998;37:552–557. [PubMed]
34. Isom AL. Barnes S. Wilson L. Kirk M. Coward L. Darley-Usmar V. Modification of cytochrome c by 4-hydroxy-2-nonenal: evidence for histidine, lysine, and arginine-aldehyde adducts. J Am Soc Mass Spectrom. 2004;15:1136–1147. [PubMed]
35. Itoh K. Wakabayashi N. Katoh Y. Ishii T. O'Connor T. Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells. 2003;8:379–391. [PubMed]
36. Ji C. Amarnath V. Pietenpol JA. Marnett LJ. 4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release. Chem Res Toxicol. 2001;14:1090–1096. [PubMed]
37. Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol. 2008;295:C849–C868. [PubMed]
38. Jyrkkanen HK. Kansanen E. Inkala M. Kivela AM. Hurttila H. Heinonen SE. Goldsteins G. Jauhiainen S. Tiainen S. Makkonen H. Oskolkova O. Afonyushkin T. Koistinaho J. Yamamoto M. Bochkov VN. Yla-Herttuala S. Levonen AL. Nrf2 regulates antioxidant gene expression evoked by oxidized phospholipids in endothelial cells and murine arteries in vivo. Circ Res. 2008;103:e1–e9. [PubMed]
39. Kagan VE. Bayir HA. Belikova NA. Kapralov O. Tyurina YY. Tyurin VA. Jiang J. Stoyanovsky DA. Wipf P. Kochanek PM. Greenberger JS. Pitt B. Shvedova AA. Borisenko G. Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic Biol Med. 2009;46:1439–1453. [PMC free article] [PubMed]
40. Kobayashi M. Li L. Iwamoto N. Nakajima-Takagi Y. Kaneko H. Nakayama Y. Eguchi M. Wada Y. Kumagai Y. Yamamoto M. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol. 2009;29:493–502. [PMC free article] [PubMed]
41. Koenitzer JR. Freeman BA. Redox signaling in inflammation: interactions of endogenous electrophiles and mitochondria in cardiovascular disease. Ann N Y Acad Sci. 2010;1203:45–52. [PubMed]
42. Kondo M. Shibata T. Kumagai T. Osawa T. Shibata N. Kobayashi M. Sasaki S. Iwata M. Noguchi N. Uchida K. 15-Deoxy-Delta(12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci U S A. 2002;99:7367–7372. [PubMed]
43. Kuhn H. Saam J. Eibach S. Holzhutter HG. Ivanov I. Walther M. Structural biology of mammalian lipoxygenases: enzymatic consequences of targeted alterations of the protein structure. Biochem Biophys Res Commun. 2005;338:93–101. [PubMed]
44. Kumar S. Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol Lett. 2005;157:175–188. [PubMed]
45. Landar A. Shiva S. Levonen AL. Oh JY. Zaragoza C. Johnson MS. Darley-Usmar VM. Induction of the permeability transition and cytochrome c release by 15-deoxy-Delta12,14-prostaglandin J2 in mitochondria. Biochem J. 2006;394:185–195. [PubMed]
46. Landar A. Zmijewski JW. Dickinson DA. Le Goffe C. Johnson MS. Milne GL. Zanoni G. Vidari G. Morrow JD. Darley-Usmar VM. Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. Am J Physiol. 2006;290:H1777–H1787. [PubMed]
47. Leff JA. Kennedy DA. Terada LS. Emmett M. McCutchan HJ. Walden DL. Repine JE. Reperfusion of ischemic skeletal muscle causes erythrocyte hemolysis and decreases subsequent oxidant-mediated lung injury. J Lab Clin Med. 1991;118:352–358. [PubMed]
48. Lemasters JJ. Theruvath TP. Zhong Z. Nieminen AL. Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta. 2009;1787:1395–1401. [PMC free article] [PubMed]
49. Levonen AL. Dickinson DA. Moellering DR. Mulcahy RT. Forman HJ. Darley-Usmar VM. Biphasic effects of 15-deoxy-delta(12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol. 2001;21:1846–1851. [PubMed]
50. Levonen AL. Inkala M. Heikura T. Jauhiainen S. Jyrkkanen HK. Kansanen E. Maatta K. Romppanen E. Turunen P. Rutanen J. Yla-Herttuala S. Nrf2 gene transfer induces antioxidant enzymes and suppresses smooth muscle cell growth in vitro and reduces oxidative stress in rabbit aorta in vivo. Arterioscler Thromb Vasc Biol. 2007;27:741–747. [PubMed]
51. Levonen AL. Landar A. Ramachandran A. Ceaser EK. Dickinson DA. Zanoni G. Morrow JD. Darley-Usmar VM. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J. 2004;378:373–382. [PubMed]
52. Liebler DC. Protein damage by reactive electrophiles: targets and consequences. Chem Res Toxicol. 2008;21:117–128. [PMC free article] [PubMed]
53. Lo SC. Hannink M. PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria. Exp Cell Res. 2008;314:1789–1803. [PMC free article] [PubMed]
54. Mak S. Lehotay DC. Yazdanpanah M. Azevedo ER. Liu PP. Newton GE. Unsaturated aldehydes including 4-OH-nonenal are elevated in patients with congestive heart failure. J Card Fail. 2000;6:108–114. [PubMed]
55. Malle E. Marsche G. Arnhold J. Davies MJ. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta. 2006;1761:392–415. [PubMed]
56. Mann GE. Niehueser-Saran J. Watson A. Gao L. Ishii T. de Winter P. Siow RC. Nrf2/ARE regulated antioxidant gene expression in endothelial and smooth muscle cells in oxidative stress: implications for atherosclerosis and preeclampsia. Sheng Li Xue Bao. 2007;59:117–127. [PubMed]
57. Martinez-Clemente M. Claria J. Titos E. The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. Curr Opin Clin Nutr Metab Care. 2011;14:347–353. [PubMed]
58. McMahon M. Itoh K. Yamamoto M. Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem. 2003;278:21592–21600. [PubMed]
59. McMahon M. Lamont DJ. Beattie KA. Hayes JD. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci U S A. 2010;107:18838–18843. [PubMed]
60. McStay GP. Clarke SJ. Halestrap AP. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem J. 2002;367:541–548. [PubMed]
61. Minhas KM. Saraiva RM. Schuleri KH. Lehrke S. Zheng M. Saliaris AP. Berry CE. Barouch LA. Vandegaer KM. Li D. Hare JM. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res. 2006;98:271–279. [PubMed]
62. Montuschi P. Barnes PJ. Roberts LJ., 2nd Isoprostanes: markers and mediators of oxidative stress. FASEB J. 2004;18:1791–1800. [PubMed]
63. Moos PJ. Edes K. Cassidy P. Massuda E. Fitzpatrick FA. Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem. 2003;278:745–750. [PubMed]
64. Nadtochiy SM. Baker PR. Freeman BA. Brookes PS. Mitochondrial nitroalkene formation and mild uncoupling in ischaemic preconditioning: implications for cardioprotection. Cardiovasc Res. 2009;82:333–340. [PMC free article] [PubMed]
65. Natta C. Machlin L. Plasma levels of tocopherol in sickle cell anemia subjects. Am J Clin Nutr. 1979;32:1359–1362. [PubMed]
66. Nguyen T. Sherratt PJ. Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol. 2003;43:233–260. [PubMed]
67. Niki E. Yoshida Y. Saito Y. Noguchi N. Lipid peroxidation: mechanisms, inhibition, and biological effects. Biochem Biophys Res Commun. 2005;338:668–676. [PubMed]
68. Oh JY. Giles N. Landar A. Darley-Usmar V. Accumulation of 15-deoxy-delta(12,14)-prostaglandin J2 adduct formation with Keap1 over time: effects on potency for intracellular antioxidant defence induction. Biochemical J. 2008;411:297–306. [PMC free article] [PubMed]
69. Ohnishi ST. Ohnishi T. Ogunmola GB. Sickle cell anemia: a potential nutritional approach for a molecular disease. Nutrition. 2000;16:330–338. [PubMed]
70. Perez-Sala D. Cernuda-Morollon E. Pineda-Molina E. Canada FJ. Contribution of covalent protein modification to the antiinflammatory effects of cyclopentenone prostaglandins. Ann N Y Acad Sci. 2002;973:533–536. [PubMed]
71. Poon HF. Calabrese V. Scapagnini G. Butterfield DA. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J Gerontol A Biol Sci Med Sci. 2004;59:478–493. [PubMed]
72. Riahi Y. Cohen G. Shamni O. Sasson S. Signaling and cytotoxic functions of 4-hydroxyalkenals. Am J Physiol Endocrinol Metab. 2010;299:E879–E886. [PubMed]
73. Ricart KC. Bolisetty S. Johnson MS. Perez J. Agarwal A. Murphy MP. Landar A. The permissive role of mitochondria in the induction of haem oxygenase-1 in endothelial cells. Biochem J. 2009;419:427–436. [PMC free article] [PubMed]
74. Ricciotti E. FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986–1000. [PMC free article] [PubMed]
75. Riley BE. Kaiser SE. Kopito RR. Autophagy inhibition engages Nrf2-p62 Ub-associated signaling. Autophagy. 2011;7:338–340. [PMC free article] [PubMed]
76. Riley BE. Kaiser SE. Shaler TA. Ng AC. Hara T. Hipp MS. Lage K. Xavier RJ. Ryu KY. Taguchi K. Yamamoto M. Tanaka K. Mizushima N. Komatsu M. Kopito RR. Ubiquitin accumulation in autophagy-deficient mice is dependent on the Nrf2-mediated stress response pathway: a potential role for protein aggregation in autophagic substrate selection. J Cell Biol. 2010;191:537–552. [PMC free article] [PubMed]
77. Rudolph TK. Freeman BA. Transduction of redox signaling by electrophile-protein reactions. Sci Signal. 2009;2:re7. [PubMed]
78. Sanchez-Gomez FJ. Gayarre J. Avellano MI. Perez-Sala D. Direct evidence for the covalent modification of glutathione-S-transferase P1-1 by electrophilic prostaglandins: implications for enzyme inactivation and cell survival. Arch Biochem Biophys. 2007;457:150–159. [PubMed]
79. Schaur RJ. Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Mol Aspects Med. 2003;24:149–159. [PubMed]
80. Scher JU. Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol. 2005;114:100–109. [PubMed]
81. Shibata T. Yamada T. Ishii T. Kumazawa S. Nakamura H. Masutani H. Yodoi J. Uchida K. Thioredoxin as a molecular target of cyclopentenone prostaglandins. J Biol Chem. 2003;278:26046–26054. [PubMed]
82. Singh IN. Sullivan PG. Hall ED. Peroxynitrite-mediated oxidative damage to brain mitochondria: Protective effects of peroxynitrite scavengers. J Neurosci Res. 2007;85:2216–2223. [PubMed]
83. Smyth EM. Grosser T. Wang M. Yu Y. FitzGerald GA. Prostanoids in health and disease. J Lipid Res. 2009;50(Suppl):S423–S428. [PubMed]
84. Sorescu D. Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail. 2002;8:132–140. [PubMed]
85. Straus DS. Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev. 2001;21:185–210. [PubMed]
86. Sugihara T. Repka T. Hebbel RP. Detection, characterization, and bioavailability of membrane-associated iron in the intact sickle red cell. J Clin Invest. 1992;90:2327–2332. [PMC free article] [PubMed]
87. Szapacs ME. Kim HY. Porter NA. Liebler DC. Identification of proteins adducted by lipid peroxidation products in plasma and modifications of apolipoprotein A1 with a novel biotinylated phospholipid probe. J Proteome Res. 2008;7:4237–4246. [PMC free article] [PubMed]
88. Touqui L. Alaoui-El-Azher M. Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr Mol Med. 2001;1:739–754. [PubMed]
89. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res. 2003;42:318–343. [PubMed]
90. Uchida K. Shiraishi M. Naito Y. Torii Y. Nakamura Y. Osawa T. Activation of stress signaling pathways by the end product of lipid peroxidation. 4-hydroxy-2-nonenal is a potential inducer of intracellular peroxide production. J Biol Chem. 1999;274:2234–2242. [PubMed]
91. Uchida Y. Ohba K. Yoshioka T. Irie K. Muraki T. Maru Y. Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathway. J Biol Chem. 2004;279:4075–4083. [PubMed]
92. Ungvari Z. Gupte SA. Recchia FA. Batkai S. Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005;3:221–229. [PMC free article] [PubMed]
93. Vila A. Tallman KA. Jacobs AT. Liebler DC. Porter NA. Marnett LJ. Identification of protein targets of 4-hydroxynonenal using click chemistry for ex vivo biotinylation of azido and alkynyl derivatives. Chem Res Toxicol. 2008;21:432–444. [PMC free article] [PubMed]
94. Warner TD. Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790–804. [PubMed]
95. Watanabe N. Zmijewski JW. Takabe W. Umezu-Goto M. Le Goffe C. Sekine A. Landar A. Watanabe A. Aoki J. Arai H. Kodama T. Murphy MP. Kalyanaraman R. Darley-Usmar VM. Noguchi N. Activation of mitogen-activated protein kinases by lysophosphatidylcholine-induced mitochondrial reactive oxygen species generation in endothelial cells. Am J Pathol. 2006;168:1737–1748. [PubMed]
96. Wong HL. Liebler DC. Mitochondrial protein targets of thiol-reactive electrophiles. Chem Res Toxicol. 2008;21:796–804. [PMC free article] [PubMed]
97. Yang J. Dong H. Hammock BD. Profiling the regulatory lipids: another systemic way to unveil the biological mystery. Curr Opin Lipidol. 2011;22:197–203. [PMC free article] [PubMed]
98. Yang K. Zhao Z. Gross RW. Han X. Identification and quantitation of unsaturated fatty acid isomers by electrospray ionization tandem mass spectrometry: a shotgun lipidomics approach. Anal Chem. 2011;83:4243–4250. [PMC free article] [PubMed]
99. Yang K. Zhao Z. Gross RW. Han X. Systematic analysis of choline-containing phospholipids using multi-dimensional mass spectrometry-based shotgun lipidomics. J Chromatogr B Anal Tech Biomed Life Sci. 2009;877:2924–2936. [PMC free article] [PubMed]
100. Zhou A. Scoggin S. Gaynor RB. Williams NS. Identification of NF-kappa B-regulated genes induced by TNFalpha utilizing expression profiling and RNA interference. Oncogene. 2003;22:2054–2064. [PubMed]
101. Zmijewski JW. Landar A. Watanabe N. Dickinson DA. Noguchi N. Darley-Usmar VM. Cell signalling by oxidized lipids and the role of reactive oxygen species in the endothelium. Biochem Soc Trans. 2005;33:1385–1389. [PMC free article] [PubMed]

Articles from Antioxidants & Redox Signaling are provided here courtesy of Mary Ann Liebert, Inc.